<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Gastroenterol</journal-id><journal-title-group><journal-title>BMC Gastroenterology</journal-title></journal-title-group><issn pub-type="epub">1471-230X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32272898</article-id><article-id pub-id-type="pmc">7147026</article-id><article-id pub-id-type="publisher-id">1235</article-id><article-id pub-id-type="doi">10.1186/s12876-020-01235-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Comparison of overall survival on surgical resection versus transarterial chemoembolization with or without radiofrequency ablation in intermediate stage hepatocellular carcinoma: a propensity score matching analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Lin</surname><given-names>Chih-Wen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Yaw-Sen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lo</surname><given-names>Gin-Ho</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Yao-Chun</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsu</surname><given-names>Chia-Chang</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Tsung-Chin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Yeh</surname><given-names>Jen-Hao</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsiao</surname><given-names>Pojen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hsieh</surname><given-names>Pei-Min</given-names></name><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Hung-Yu</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Shu</surname><given-names>Chih-Wen</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hung</surname><given-names>Chao-Ming</given-names></name><address><email>ed101968@edah.org.tw</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>Division of Gastroenterology and Hepatology, E-Da Dachang Hospital, </institution><institution>I-Shou University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>Division of Gastroenterology and Hepatology, Department of Medicine, E-Da Hospital, </institution><institution>I-Shou University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>Health Examination Center, E-Da Hospital, </institution><institution>I-Shou University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>School of Medicine, College of Medicine, </institution><institution>I-Shou University, </institution></institution-wrap>82445, No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, Taiwan </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.412019.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 9476 5696</institution-id><institution>Graduate Institute of Medicine, College of Medicine, </institution><institution>Kaohsiung Medical University, </institution></institution-wrap>Kaohsiung, Taiwan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.254145.3</institution-id><institution-id institution-id-type="ISNI">0000 0001 0083 6092</institution-id><institution>School of Chinese Medicine, College of Chinese Medicine, </institution><institution>China Medical University, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.411508.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0572 9415</institution-id><institution>Research Center for Traditional Chinese Medicine, </institution><institution>China Medical University Hospital, </institution></institution-wrap>Taichung, Taiwan </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>Department of Surgery, E-Da Hospital, </institution><institution>I-Shou University, </institution></institution-wrap>No. 1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung, 82445 Taiwan </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.411447.3</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 1806</institution-id><institution>Department of Surgery, E-Da Cancer Hospital, </institution><institution>I-Shou University, </institution></institution-wrap>Kaohsiung, Taiwan </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>4</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>20</volume><elocation-id>99</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2020</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) are recommended to undergo transcatheter arterial chemoembolization (TACE). However, TACE in combination with radiofrequency ablation (RFA) is not inferior to surgical resection (SR), and the benefits of surgical resection (SR) for BCLC stage B HCC remain unclear. Hence, this study aims to compare the impact of SR, TACE+RFA, and TACE on analyzing overall survival (OS) in BCLC stage B HCC.</p></sec><sec><title>Methods</title><p id="Par2">Overall, 428 HCC patients were included in BCLC stage B, and their clinical data and OS were recorded. OS was analyzed by the Kaplan-Meier method and Cox regression analysis.</p></sec><sec><title>Results</title><p id="Par3">One hundred forty (32.7%) patients received SR, 57 (13.3%) received TACE+RFA, and 231 (53.9%) received TACE. The OS was significantly higher in the SR group than that in the TACE+RFA group [hazard ratio (HR): 1.78; 95% confidence incidence (CI): 1.15&#x02013;2.75, <italic>p</italic>&#x02009;=&#x02009;0.009]. The OS was significantly higher in the SR group than that in the TACE group (HR: 3.17; 95% CI: 2.31&#x02013;4.36, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001). Moreover, the OS was significantly higher in the TACE+RFA group than that in the TACE group (HR: 1.82; 95% CI: 1.21&#x02013;2.74, <italic>p</italic>&#x02009;=&#x02009;0.004). The cumulative OS rates at 1, 3 and 5&#x02009;years in the SR, TACE+RFA, and TACE groups were 89.2, 69.4 and 61.2%, 86.0, 57.9 and 38.2%, and 69.5, 37.0 and 15.2%, respectively. After propensity score matching, the SR group still had a higher OS than those of the TACE+RFA and TACE groups. The TACE+RFA group had a higher OS than that of the TACE group.</p></sec><sec><title>Conclusion</title><p id="Par4">The SR group had higher OS than the TACE+RFA and TACE groups in BCLC stage B HCC. Furthermore, the TACE+RFA group had higher OS than the TACE group.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatocellular carcinoma</kwd><kwd>Barcelona clinic liver Cancer stage B</kwd><kwd>Overall survival</kwd><kwd>Surgical resection</kwd><kwd>Transcatheter arterial chemoembolization</kwd><kwd>Radiofrequency ablation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004663</institution-id><institution>Ministry of Science and Technology, Taiwan</institution></institution-wrap></funding-source><award-id>108-2314-B-214-006-MY2</award-id><principal-award-recipient><name><surname>Lin</surname><given-names>Chih-Wen</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par24">Hepatocellular carcinoma (HCC) is the fifth most common cancer but the third most lethal cancer worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. The Barcelona Clinic Liver Cancer (BCLC) system is widely utilized in the American Association for the Study of Liver Disease (AASLD), European Association for the Study of Liver (EASL) and Asian-Pacific Associated for the Study of the Liver (APASL) guidelines for the treatment of HCC [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Patients with stage B (intermediate stage) HCC are recommended to undergo transcatheter arterial chemoembolization (TACE) based on the BCLC system [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. However, surgical resection (SR) and radiofrequency ablation (RFA) are curative therapies in BCLC stage 0/A and are alternative therapies for selected patients with BCLC stage B in clinical practice [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Previous studies have shown that TACE combined with RFA (TACE+RFA) has a better overall survival (OS) than TACE in BCLC stage B [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, some studies have shown that SR can have a better OS than TACE with or without RFA in BCLC stage B [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. However, TACE+RFA is not inferior to SR for patients with HCC within the Milan criteria [<xref ref-type="bibr" rid="CR10">10</xref>]. Furthermore, TACE + RFA is not inferior to SR for patients with HCC within BCLC stage A or B after propensity score-based analysis [<xref ref-type="bibr" rid="CR6">6</xref>]. Hence, this study aims to compare the impact of SR, TACE + RFA, and TACE on the OS of HCC patients with BCLC stage B. Each patient was treated with one of these three therapies. Furthermore, we compared the OS of patients in each group using propensity score matching (PSM) to minimize potential bias in the results.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and follow-up</title><p id="Par25">We retrospectively collected information on 2680 patients diagnosed with HCC between 2011 and 2018 at E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. Two thousand and one hundred forty-six patients were excluded due to BCLC stage 0, A, C, and D, and 110 patients had incomplete data in BCLC stage B. Finally, 428 patients with BCLC stage B were included in this retrospective study (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). The study was conducted in accordance with the guidelines of the International Conference on Harmonization for Good Clinical Practice and was approved by the Ethics Committee of E-Da Hospital, I-Shou University (EMRP-107-130). Patients were diagnosed with HCC based on histological confirmation or at least one typical imaging method according to the recommendations of the AASLD [<xref ref-type="bibr" rid="CR2">2</xref>]. Clinicopathological parameters, including demographic data, smoking, excessive alcohol use, hepatitis status, serum total bilirubin, international normalization ratio (INR), liver cirrhosis, Child-Pugh (CP) class, tumor size, tumor number, alpha-fetoprotein (AFP), mortality, and follow-up time, were examined. Tumor number and tumor size were mostly determined based on radiologic findings and confirmed by pathologic findings if appropriate. Liver cirrhosis was diagnosed based on pathologic findings and/or evaluated by ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). The functional status of the liver was evaluated using the CP scoring system.
<fig id="Fig1"><label>Fig. 1</label><caption><p>Study flowchart and inclusion of participants</p></caption><graphic xlink:href="12876_2020_1235_Fig1_HTML" id="MO1"/></fig></p><p id="Par26">Patients were treated with SR, TACE+RFA, and TACE, and our multidisciplinary team chose suitable therapy. The criteria for SR were resectable tumors, sufficient residual liver volume, CP class A or selected CP class B patients, or absence of ascites and hypersplenism. The indications of TACE+RFA were CP class A or B and absent ascites. The indications of TACE were CP class A or B and absent massive ascites. Patients were divided into the SR group, TACE+RFA group, and TACE group.</p><p id="Par27">Patients were followed up every three to 6 months by abdominal ultrasound, CT or MRI and AFP. OS was defined as the time from the date of diagnosis to the date of death or last visit, and the last follow-up time was June 2019.</p></sec><sec id="Sec4"><title>Data analysis and statistics</title><p id="Par28">All statistical analyses were performed using SPSS ver. 23.0 (SPSS, Chicago, IL, USA). Numerical data were expressed as medians and ranges. Categorical data were described using numbers and percentages. OS was determined using the Kaplan-Meier method and compared with patients receiving different treatments. Cox proportional hazards regression analysis of OS in HCC patients was performed according to different treatments. Moreover, we used logistic regression to perform PSM with sex, age, cirrhosis, CP class, tumor size, and tumor number for patients to reduce bias in our analyses. Each treatment group was matched with the control group (SR group or TACE group) according to the generated PSM using a caliper width of 0.2. On the completion of matching, the baseline covariates were compared using the paired t-test or Mann&#x02013;Whitney U test for continuous variables and the chi-square test for categorical variables. A <italic>p</italic>-value &#x0003c;&#x02009;0.05 was used to determine statistical significance.</p></sec></sec><sec id="Sec5"><title>Results</title><sec id="Sec6"><title>Baseline demographic data before propensity score matching</title><p id="Par29">A total of 428 HCC patients were included in this study (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The demographic and clinical features of the 428 patients (77.8% male, median age of 63&#x02009;years) are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Regarding the etiology of HCC, 47.9% of the patients had HBV infection, 32.4% had HCV infection, and 42.3% had excessive alcohol use. Approximately 54.7% of patients had liver cirrhosis, and of those patients, 86.9% had CP class A disease. Many (67.5%) of the patients had tumors &#x02265;5&#x02009;cm in size, and 65.0% of the patients had multiple tumors.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Basic demographic data of patients with BCLC stage B hepatocellular carcinoma of various treatments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>SR (<italic>n</italic>&#x02009;=&#x02009;140)</th><th>TACE (<italic>n</italic>&#x02009;=&#x02009;231)</th><th>TACE+RFA (<italic>n</italic>&#x02009;=&#x02009;57)</th><th>Total (<italic>n</italic>&#x02009;=&#x02009;428)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td>Male</td><td>117 (83.6)</td><td>173 (74.9)</td><td>43 (75.4)</td><td>333 (77.8)</td><td>0.134</td></tr><tr><td>Age (years)</td><td>62 (35&#x02013;82)</td><td>64 (29&#x02013;91)</td><td>64 (28&#x02013;86)</td><td>63 (25&#x02013;91)</td><td>0.311</td></tr><tr><td>Smoking</td><td>68 (48.6)</td><td>113 (48.9)</td><td>27 (47.4)</td><td>208 (48.6)</td><td>0.978</td></tr><tr><td>Alcohol use</td><td>58 (41.4)</td><td>100 (43.3)</td><td>23 (40.4)</td><td>181 (42.3)</td><td>0.894</td></tr><tr><td>HBV positive</td><td>70 (50.0)</td><td>103 (44.6)</td><td>32 (56.1)</td><td>205 (47.9)</td><td>0.245</td></tr><tr><td>HCV positive</td><td>30 (21.4)</td><td>90 (39.0)</td><td>21 (36.8)</td><td>141 (32.9)</td><td>0.002</td></tr><tr><td>Total Bilirubin</td><td>1.03&#x02009;&#x000b1;&#x02009;0.43</td><td>1.34&#x02009;&#x000b1;&#x02009;1.14</td><td>1.40&#x02009;&#x000b1;&#x02009;0.66</td><td>1.24&#x02009;&#x000b1;&#x02009;0.91</td><td>0.003</td></tr><tr><td>INR</td><td>1.00&#x02009;&#x000b1;&#x02009;0.06</td><td>1.06&#x02009;&#x000b1;&#x02009;0.12</td><td>1.10&#x02009;&#x000b1;&#x02009;0.14</td><td>1.05&#x02009;&#x000b1;&#x02009;0.11</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>Cirrhosis</td><td>36 (25.7)</td><td>155 (67.1)</td><td>43 (75.4)</td><td>234 (54.7)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>Child-Pugh class A</td><td>134 (95.7)</td><td>194 (84.0)</td><td>44 (77.2)</td><td>372 (86.9)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>Tumor size</td><td>8.2&#x02009;&#x000b1;&#x02009;3.3</td><td>7.0&#x02009;&#x000b1;&#x02009;3.8</td><td>5.5&#x02009;&#x000b1;&#x02009;2.6</td><td>7.0&#x02009;&#x000b1;&#x02009;3.6</td><td>0.001</td></tr><tr><td>Tumor size&#x02265;5&#x02009;cm</td><td>127 (90.7)</td><td>149 (64.5)</td><td>25 (43.8)</td><td>289 (67.5)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>Tumor number (&#x02265;3)</td><td>49 (35.0)</td><td>178 (77.1)</td><td>51 (89.5)</td><td>278 (65.0)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>AFP (ng/mL)&#x02009;&#x02265;&#x02009;200</td><td>34 (24.3)</td><td>50 (21.6)</td><td>7 (12.1)</td><td>91(21.3)</td><td>0.171</td></tr><tr><td>Mortality</td><td>50 (35.7)</td><td>173 (74..9)</td><td>34 (59.6)</td><td>257 (60.0)</td><td>&#x0003c;&#x02009;0.0001</td></tr><tr><td>Follow-up times (months)</td><td>39 (1&#x02013;98)</td><td>22 (1&#x02013;97)</td><td>37 (3&#x02013;95)</td><td>29 (1&#x02013;98)</td><td>&#x0003c;&#x02009;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>BCLC stage</italic> Barcelona clinic liver cancer; <italic>SR</italic> Surgical resection; <italic>TACE</italic> Transcatheter arterial chemoembolization; <italic>RFA</italic> Radiofrequency ablation; <italic>HBV</italic> Hepatitis B virus; <italic>HCV</italic> Hepatitis C virus; <italic>AFP: INR</italic> International normalize ratio; Alpha-fetoprotein;</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec7"><title>Overall survival of patients in the total and different treatment groups</title><p id="Par30">Of the 428 patients, 257 (60.0%) died, and the median follow-up duration was 29 (range, 1&#x02013;98) months (Table <xref rid="Tab1" ref-type="table">1</xref>). The mortality rate was 24.8% per person-year. The cumulative OS rates at 1, 3, and 5&#x02009;years were 80.8, 50.6 and 32.8%, respectively (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a). Among the 428 patients, 140 (32.7%) patients received SR, 231 (53.9%) received TACE+RFA, and 57 (13.3%) received TACE (Table <xref rid="Tab1" ref-type="table">1</xref>). The OS was significantly better in the SR group than in the TACE+RFA group (HR: 1.78; 95% CI: 1.15&#x02013;2.75, <italic>p</italic>&#x02009;=&#x02009;0.009, Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). The OS was significantly better in the SR group than in the TACE group (HR: 3.17; 95% CI: 2.31&#x02013;4.36, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). Moreover, the OS was significantly better in the TACE+RFA group than in the TACE group (HR: 1.82; 95% CI: 1.21&#x02013;2.74, <italic>p</italic>&#x02009;=&#x02009;0.004, Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). The cumulative OS rates at 1, 3 and 5&#x02009;years in the SR, TACE+RFA, and TACE groups were 89.2, 69.4 and 61.2%, 86.0, 57.9 and 38.2%, and 69.5, 37.0 and 15.2%, respectively (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b).
<fig id="Fig2"><label>Fig. 2</label><caption><p>Overall survival in Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma (HCC) patients. Overall survival in all 428 HCC patients (<bold>a</bold>). Overall survival based on Cox regression analysis in HCC patients with different treatments before propensity score matching (<bold>b</bold>)</p></caption><graphic xlink:href="12876_2020_1235_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec8"><title>Baseline demographic data after propensity score matching</title><p id="Par31">The SR group showed significant differences compared with the TACE+RFA and TACE groups with respect to baseline features before PSM. The SR group had significantly lower rate of HCV infection cirrhosis, tumor number, and mortality, lower serum total bilirubin and INR level, and higher rate of CP class A and tumor size compared to the TACE+RFA and TACE groups (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (Table <xref rid="Tab1" ref-type="table">1</xref>). The PSM was performed with sex, age, cirrhosis, CP class, tumor size, and tumor number, and there were no significant differences for the important features (Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of surgical resection versus transarterial chemoembolization with or without radiofrequency ablation of patients withBCLC stage B hepatocellular carcinoma after propensity score matching</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>SR (<italic>n</italic>&#x02009;=&#x02009;140)</th><th>TACE+RFA (<italic>n</italic>&#x02009;=&#x02009;16)</th><th>P-value</th><th>SR (<italic>n</italic>&#x02009;=&#x02009;140)</th><th>TACE (<italic>n</italic>&#x02009;=&#x02009;87)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td>Male</td><td>117 (83.6)</td><td>13 (81.3)</td><td>0.220</td><td>117 (83.6)</td><td>67 (77.0)</td><td>0.813</td></tr><tr><td>Age (years)</td><td>62 (35&#x02013;82)</td><td>66 (35&#x02013;87)</td><td>0.249</td><td>62 (35&#x02013;82)</td><td>64 (36&#x02013;87)</td><td>0.121</td></tr><tr><td>Smoking</td><td>68 (48.6)</td><td>8 (50.0)</td><td>0.472</td><td>68 (48.6)</td><td>38 (43.7)</td><td>0.914</td></tr><tr><td>Alcohol use</td><td>58 (41.4)</td><td>7 (43.8)</td><td>0.858</td><td>58 (41.4)</td><td>35 (40.2)</td><td>0.858</td></tr><tr><td>HBV positive</td><td>70 (50.0)</td><td>10 (62.5)</td><td>0.206</td><td>70 (50.0)</td><td>36 (41.4)</td><td>0.343</td></tr><tr><td>HCV positive</td><td>30 (21.4)</td><td>6 (16.7)</td><td>0.069</td><td>30 (21.4)</td><td>26 (29.8)</td><td>0.148</td></tr><tr><td>Total Bilirubin</td><td>1.03&#x02009;&#x000b1;&#x02009;0.43</td><td>1.21&#x02009;&#x000b1;&#x02009;0.54</td><td>0.186</td><td>1.03&#x02009;&#x000b1;&#x02009;0.43</td><td>1.11&#x02009;&#x000b1;&#x02009;0.50</td><td>0.061</td></tr><tr><td>INR</td><td>1.00&#x02009;&#x000b1;&#x02009;0.06</td><td>1.04&#x02009;&#x000b1;&#x02009;0.10</td><td>0.061</td><td>1.00&#x02009;&#x000b1;&#x02009;0.06</td><td>1.03&#x02009;&#x000b1;&#x02009;0.09</td><td>0.051</td></tr><tr><td>Cirrhosis</td><td>36 (25.7)</td><td>6 (37.5)</td><td>0.098</td><td>36 (25.7)</td><td>31 (35.6)</td><td>0.111</td></tr><tr><td>Child-Pugh class A</td><td>134 (95.7)</td><td>14 (87.5)</td><td>0.236</td><td>134 (95.7)</td><td>80 (92.7)</td><td>0.158</td></tr><tr><td>Tumor size</td><td>8.2&#x02009;&#x000b1;&#x02009;3.3</td><td>6.6&#x02009;&#x000b1;&#x02009;2.8</td><td>0.903</td><td>8.2&#x02009;&#x000b1;&#x02009;3.3</td><td>8.2&#x02009;&#x000b1;&#x02009;3.5</td><td>0.063</td></tr><tr><td>Tumor size&#x02265;5&#x02009;cm</td><td>127 (90.7)</td><td>12 (75.0)</td><td>0.186</td><td>127 (90.7)</td><td>75 (86.2)</td><td>0.071</td></tr><tr><td>Tumor number (&#x02265;3)</td><td>49 (35.0)</td><td>9 (56.2)</td><td>0.075</td><td>49 (35.0)</td><td>41 (47.1)</td><td>0.058</td></tr><tr><td>AFP (ng/mL)&#x02009;&#x02265;&#x02009;200</td><td>34 (24.3)</td><td>2 (12.5)</td><td>0.405</td><td>34 (24.3)</td><td>17 (19.5)</td><td>0.289</td></tr><tr><td>Mortality</td><td>50 (35.7)</td><td>11 (68.8)</td><td>&#x0003c;&#x02009;0.0001</td><td>50 (35.7)</td><td>70 (80.5)</td><td>0.010</td></tr><tr><td>Follow up times (months)</td><td>39 (1&#x02013;98)</td><td>26 (9&#x02013;76)</td><td>&#x0003c;&#x02009;0.0001</td><td>39 (1&#x02013;98)</td><td>21 (2&#x02013;97)</td><td>0.240</td></tr></tbody></table><table-wrap-foot><p><italic>BCLC stage</italic> Barcelona clinic liver cancer; <italic>SR</italic> Surgical resection; <italic>TACE</italic> Transcatheter arterial chemoembolization; <italic>RFA</italic> Radiofrequency ablation; <italic>HBV</italic> Hepatitis B virus; <italic>HCV</italic> Hepatitis C virus; <italic>AFP: INR</italic> International normalize ratio; Alpha-fetoprotein;</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of transarterial chemoembolization with radiofrequency ablation versus transarterial chemoembolization of patients with BCLC stage B hepatocellular carcinoma after propensity score matching</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>TACE+RFA (<italic>n</italic>&#x02009;=&#x02009;56)</th><th>TACE (<italic>n</italic>&#x02009;=&#x02009;231)</th><th><italic>P</italic>-value</th></tr></thead><tbody><tr><td>Male</td><td>42 (75.0)</td><td>173 (74.9)</td><td>0.987</td></tr><tr><td>Age (years)</td><td>64 (28&#x02013;86)</td><td>64 (29&#x02013;91)</td><td>0.672</td></tr><tr><td>Smoking</td><td>27 (47.4)</td><td>113 (48.9)</td><td>0.925</td></tr><tr><td>Alcohol use</td><td>23 (40.4)</td><td>100 (43.3)</td><td>0.763</td></tr><tr><td>HBV positive</td><td>32 (56.1)</td><td>103 (44.6)</td><td>0.091</td></tr><tr><td>HCV positive</td><td>21 (36.8)</td><td>90 (39.0)</td><td>0.085</td></tr><tr><td>Total Bilirubin</td><td>1.41&#x02009;&#x000b1;&#x02009;0.67</td><td>1.34&#x02009;&#x000b1;&#x02009;1.14</td><td>0.643</td></tr><tr><td>INR</td><td>1.10&#x02009;&#x000b1;&#x02009;0.14</td><td>1.06&#x02009;&#x000b1;&#x02009;0.12</td><td>0.060</td></tr><tr><td>Cirrhosis</td><td>43 (75.4)</td><td>155 (67.1)</td><td>0.160</td></tr><tr><td>Child-Pugh class A</td><td>43 (76.8)</td><td>194 (84.0)</td><td>0.203</td></tr><tr><td>Tumor size</td><td>5.5&#x02009;&#x000b1;&#x02009;2.6</td><td>7.0&#x02009;&#x000b1;&#x02009;3.8</td><td>0.062</td></tr><tr><td>Tumor size&#x02265;5&#x02009;cm</td><td>25 (44.6)</td><td>149 (64.5)</td><td>0.053</td></tr><tr><td>Tumor number (&#x02265;3)</td><td>50 (89.3)</td><td>178 (77.1)</td><td>0.051</td></tr><tr><td>AFP (ng/mL)&#x02009;&#x02265;&#x02009;200</td><td>6 (10.7)</td><td>50 (21.6)</td><td>0.064</td></tr><tr><td>Mortality</td><td>34 (59.6)</td><td>173 (74..9)</td><td>0.034</td></tr><tr><td>Follow up times (months)</td><td>36 (3&#x02013;95)</td><td>22 (1&#x02013;97)</td><td>&#x0003c;&#x02009;0.0001</td></tr></tbody></table><table-wrap-foot><p><italic>BCLC stage</italic>: Barcelona clinic liver cancer; <italic>SR</italic> Surgical resection; <italic>TACE</italic> Transcatheter arterial chemoembolization; <italic>RFA</italic> Radiofrequency ablation; <italic>HBV</italic> Hepatitis B virus; <italic>HCV</italic> Hepatitis C virus; <italic>AFP: INR</italic> International normalize ratio; Alpha-fetoprotein;</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Overall survival of patients in the different treatment groups after propensity score matching</title><p id="Par32">In the SR group versus TACE+RFA group after PSM (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), 140 patients underwent SR, and 16 patients received TACE+RFA. Patients undergoing SR had significantly higher survival rates than patients receiving TACE+RFA (HR: 2.33; 95% CI: 1.21&#x02013;4.49, <italic>p</italic>&#x02009;=&#x02009;0.011, Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a). The cumulative OS rates at 1, 3 and 5&#x02009;years in the SR and TACE+RFA groups were 89.2, 69.4 and 61.2% and 81.3, 50.0 and 26.8%, respectively (Figs. <xref rid="Fig3" ref-type="fig">3</xref>a).
<fig id="Fig3"><label>Fig. 3</label><caption><p>Overall survival according to different treatments after propensity score matching. Comparison of overall survival between surgical resection (SR) versus transarterial chemoembolization (TACE) with radiofrequency ablation (RFA) (<bold>a</bold>). Comparison of overall survival between SR versus TACE (<bold>b</bold>). Comparison of overall survival between TACE+RFA versus TACE (<bold>c</bold>)</p></caption><graphic xlink:href="12876_2020_1235_Fig3_HTML" id="MO3"/></fig></p><p id="Par33">In the SR group versus TACE group after PSM (Table <xref rid="Tab2" ref-type="table">2</xref>), 140 patients underwent SR, and 87 patients received TACE. Patients undergoing SR had significantly higher survival rates than patients receiving TACE treatments (HR: 3.10; 95% CI: 2.15&#x02013;4.46, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Figs. <xref rid="Fig3" ref-type="fig">3</xref>b). The cumulative OS rates at 1, 3 and 5&#x02009;years in the SR and TACE groups were 89.2, 69.4 and 61.2% and 70.1, 36.3 and 15.7%, respectively (Figs. <xref rid="Fig3" ref-type="fig">3</xref>b).</p><p id="Par34">In the TACE+RFA group versus TACE group after PSM (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), 56 patients received TACE+RFA, and 231 patients received TACE. Patients undergoing TACE+RFA had significantly higher survival rates than patients receiving TACE treatments (HR: 1.77; 95% CI: 1.22&#x02013;2.56, <italic>p</italic>&#x02009;=&#x02009;0.002, Figs. <xref rid="Fig3" ref-type="fig">3</xref>c). The cumulative OS rates at 1, 3 and 5&#x02009;years in the TACE+RFA and TACE groups were 85.7, 57.1 and 37.7% and 73.5, 37.0 and 15.2%, respectively (Figs. <xref rid="Fig3" ref-type="fig">3</xref>c).</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par35">Patients with BCLC stage B are recommended to receive TACE based on the BCLC system [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Our study showed that the SR group had higher OS than the TACE+RFA and TACE groups in BCLC stage B. Furthermore, the TACE+RFA group had higher OS than the TACE group. After PSM, the SR group still had higher OS than the TACE+RFA and TACE groups. In addition, the TACE+RFA group also had higher OS than the TACE group. SR should be considered a recommended treatment for select HCC patients in BCLC stage B.</p><p id="Par36">TACE is recommended as a standard of care for the treatment of patients with BCLC stage B disease [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. Several HCC experts have proposed four substages based on the Eastern Cooperative Oncology Group performance, CP class, and &#x0201c;up-to-7&#x0201d; criteria within BCLC stage B disease [<xref ref-type="bibr" rid="CR11">11</xref>]. However, these criteria mostly indicate benefits from TACE. Based on the great improvements in surgical techniques and perioperative care, some treatments may not be suitable for patients with BCLC stage B HCC. Our results showed that SR resulted in a significantly higher OS rate than TACE+RFA and TACE in patients with BCLC stage B disease. Similarly, several studies from both Western and Eastern countries have demonstrated that SR results had higher long-term survival than nonsurgical treatments, even for patients with multiple tumors [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR12">12</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. Furthermore, compared with TACE, SR significantly increases survival in select patients with BCLC stage B HCC [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, SR is a safe and effective therapy for select patients with resectable single or multiple HCC lesions and preserved liver function. Hence, SR may be recommended for select patients with BCLC stage B disease.</p><p id="Par37">A previous study showed that TACE+RFA is safe and as effective as SR for patients with HCC within the Milan criteria and BCLC stage B [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Our study demonstrated that the SR group had a higher OS than the TACE+RFA group, although the SR group had larger tumor sizes but fewer tumor numbers than the TACE+RFA group. After PSM with sex, age, tumor size, tumor number, cirrhosis, and CP class, the SR group still had higher OS than the TACE+RFA group. Our study first demonstrated that SR has a significantly higher OS than TACE+RFA in the literature. Indeed, SR may be considered for select patients who fit these criteria and could be recommended for patients with BCLC stage B disease.</p><p id="Par38">Our study showed that the TACE+RFA group had a higher OS than the TACE group, although the TACE+RFA group had smaller tumor sizes and more tumor numbers than the TACE group. After PSM, the TACE+RFA group still had a higher OS than the TACE group. Our study is consistent with previous studies showing that TACE+RFA has a better OS than TACE in BCLC stage B [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Hence, combination TACE and RFA treatment may be considered for select patients who were multiple tumors with smaller tumor sizes and could be recommended for patients with BCLC stage B disease.</p><p id="Par39">Our study has several limitations. First, we did not take into consideration comorbidity and antiviral therapy on OS. Second, we did not consider the possible differences in TACE cycles. Third, as with all retrospective studies, there was some selection bias despite our use of PSM. Furthermore, a randomized study between the different treatments will be performed.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par40">The SR group had higher OS than the TACE+RFA and TACE groups. Furthermore, the TACE+RFA group had higher OS than the TACE group in BCLC stage B.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HCC</term><def><p id="Par5">Hepatocellular carcinoma</p></def></def-item><def-item><term>BCLC</term><def><p id="Par6">Barcelona Clinic Liver Cancer</p></def></def-item><def-item><term>AASLD</term><def><p id="Par7">American Association for the Study of Liver Disease</p></def></def-item><def-item><term>EASL</term><def><p id="Par8">European Association for the Study of Liver</p></def></def-item><def-item><term>APASL</term><def><p id="Par9">Asian-Pacific Associated for the Study of the Liver</p></def></def-item><def-item><term>SR</term><def><p id="Par10">Surgical resection</p></def></def-item><def-item><term>RFA</term><def><p id="Par11">Radiofrequency ablation</p></def></def-item><def-item><term>TACE</term><def><p id="Par12">Transcatheter arterial chemoembolization</p></def></def-item><def-item><term>PSM</term><def><p id="Par13">Propensity score matching</p></def></def-item><def-item><term>CP class</term><def><p id="Par14">Child-Pugh class</p></def></def-item><def-item><term>OS</term><def><p id="Par15">overall survival</p></def></def-item><def-item><term>HBV</term><def><p id="Par16">Hepatitis B virus</p></def></def-item><def-item><term>HCV</term><def><p id="Par17">Hepatitis C virus</p></def></def-item><def-item><term>AFP</term><def><p id="Par18">Alpha-fetoprotein</p></def></def-item><def-item><term>INR</term><def><p id="Par19">International normalize ratio</p></def></def-item><def-item><term>CT</term><def><p id="Par20">Computed tomography</p></def></def-item><def-item><term>MRI</term><def><p id="Par21">Magnetic resonance imaging</p></def></def-item><def-item><term>HR</term><def><p id="Par22">Hazard ratio</p></def></def-item><def-item><term>CI</term><def><p id="Par23">Confidence interval</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Chih-Wen Lin and Yaw-Sen Chen contributed equally to this work.</p></fn></fn-group><ack><p>We appreciated Huang Ya Ling to collect data.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>CWL and YSC: study concept and design; acquisition of data; analysis and interpretation of data; drafting of the manuscript; GHL, YCH, CCH, TCW, JHY,PH, PHM, HYL, and CWS: study concept and design; critical revision of the manuscript for important intellectual content; administrative, technical, or material support; CMH: study concept and design; analysis and interpretation of data; critical revision of the manuscript for important intellectual content administrative, technical, or material support; study supervision. All authors approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by grants from Ministry of Science Technology (108&#x02013;2314-B-214-006-MY2) to Chih-Wen Lin. The funders had a role in study design, decision to publish and preparation of the manuscript. No additional external funding was received for this study.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>Data is available from the corresponding author upon reasonable request.</p></notes><notes><title>Ethics approval and consent to participate</title><p id="Par41">The study was conducted in accordance with the guidelines of the International Conference on Harmonization for Good Clinical Practice and was approved by the Ethics Committee of E-Da Hospital, I-Shou University (EMRP-107-130).</p><p id="Par42">Informed consent for study participation is not applicable.</p></notes><notes><title>Consent for publication</title><p id="Par43">Not applicable.</p></notes><notes notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare that they have no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertuccio</surname><given-names>P</given-names></name><name><surname>Turati</surname><given-names>F</given-names></name><name><surname>Carioli</surname><given-names>G</given-names></name><name><surname>Rodriguez</surname><given-names>T</given-names></name><name><surname>La Vecchia</surname><given-names>C</given-names></name><name><surname>Malvezzi</surname><given-names>M</given-names></name><name><surname>Negri</surname><given-names>E</given-names></name></person-group><article-title>Global trends and predictions in hepatocellular carcinoma mortality</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><issue>2</issue><fpage>302</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.03.011</pub-id><pub-id pub-id-type="pmid">28336466</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heimbach</surname><given-names>JK</given-names></name><name><surname>Kulik</surname><given-names>LM</given-names></name><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Sirlin</surname><given-names>CB</given-names></name><name><surname>Abecassis</surname><given-names>MM</given-names></name><name><surname>Roberts</surname><given-names>LR</given-names></name><name><surname>Zhu</surname><given-names>AX</given-names></name><name><surname>Murad</surname><given-names>MH</given-names></name><name><surname>Marrero</surname><given-names>JA</given-names></name></person-group><article-title>AASLD guidelines for the treatment of hepatocellular carcinoma</article-title><source>Hepatology</source><year>2018</year><volume>67</volume><issue>1</issue><fpage>358</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1002/hep.29086</pub-id><pub-id pub-id-type="pmid">28130846</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>Electronic address eee, European Association for the Study of the L: EASL clinical practice guidelines: management of hepatocellular carcinoma</article-title><source>J Hepatol</source><year>2018</year><volume>69</volume><issue>1</issue><fpage>182</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.019</pub-id><pub-id pub-id-type="pmid">29628281</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Kokudo</surname><given-names>N</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Tateishi</surname><given-names>R</given-names></name><name><surname>Han</surname><given-names>KH</given-names></name><name><surname>Chawla</surname><given-names>YK</given-names></name><name><surname>Shiina</surname><given-names>S</given-names></name><etal/></person-group><article-title>Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update</article-title><source>Hepatol Int</source><year>2017</year><volume>11</volume><issue>4</issue><fpage>317</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1007/s12072-017-9799-9</pub-id><pub-id pub-id-type="pmid">28620797</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>JH</given-names></name><name><surname>Xiang</surname><given-names>BD</given-names></name><name><surname>Gong</surname><given-names>WF</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Mo</surname><given-names>QG</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>LQ</given-names></name></person-group><article-title>Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>7</issue><fpage>e68193</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0068193</pub-id><pub-id pub-id-type="pmid">23874536</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xue</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Niu</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>Comparison of macrovascular invasion-free survival in early-intermediate hepatocellular carcinoma after different interventions: a propensity score-based analysis</article-title><source>J Cancer</source><year>2019</year><volume>10</volume><issue>17</issue><fpage>4063</fpage><lpage>4071</lpage><pub-id pub-id-type="doi">10.7150/jca.29850</pub-id><pub-id pub-id-type="pmid">31417651</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>AJ</given-names></name><name><surname>Lau</surname><given-names>WY</given-names></name><name><surname>Pan</surname><given-names>ZY</given-names></name><name><surname>Lai</surname><given-names>EC</given-names></name><name><surname>Wu</surname><given-names>MC</given-names></name><name><surname>Zhou</surname><given-names>WP</given-names></name></person-group><article-title>Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT</article-title><source>J Hepatol</source><year>2014</year><volume>61</volume><issue>1</issue><fpage>82</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2014.03.012</pub-id><pub-id pub-id-type="pmid">24650695</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimose</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Iwamoto</surname><given-names>H</given-names></name><name><surname>Niizeki</surname><given-names>T</given-names></name><name><surname>Shirono</surname><given-names>T</given-names></name><name><surname>Aino</surname><given-names>H</given-names></name><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Kamachi</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: comparison with TACE alone using decision-tree analysis after propensity score matching</article-title><source>Hepatol Res</source><year>2019</year><volume>49</volume><issue>8</issue><fpage>919</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1111/hepr.13348</pub-id><pub-id pub-id-type="pmid">30969006</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Mei</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name></person-group><article-title>Transarterial chemoembolization combined with radiofrequency ablation in the treatment of stage B1 intermediate hepatocellular carcinoma</article-title><source>J Oncol</source><year>2019</year><volume>2019</volume><fpage>6298502</fpage><pub-id pub-id-type="pmid">31636667</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bholee</surname><given-names>AK</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name></person-group><article-title>Radiofrequency ablation combined with transarterial chemoembolization versus hepatectomy for patients with hepatocellular carcinoma within Milan criteria: a retrospective case-control study</article-title><source>Clin Transl Oncol</source><year>2017</year><volume>19</volume><issue>7</issue><fpage>844</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1007/s12094-016-1611-0</pub-id><pub-id pub-id-type="pmid">28070766</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolondi</surname><given-names>L</given-names></name><name><surname>Burroughs</surname><given-names>A</given-names></name><name><surname>Dufour</surname><given-names>JF</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name><name><surname>Piscaglia</surname><given-names>F</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Sangro</surname><given-names>B</given-names></name></person-group><article-title>Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions</article-title><source>Semin Liver Dis</source><year>2012</year><volume>32</volume><issue>4</issue><fpage>348</fpage><lpage>359</lpage><pub-id pub-id-type="pmid">23397536</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forner</surname><given-names>A</given-names></name><name><surname>Gilabert</surname><given-names>M</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name></person-group><article-title>Treatment of intermediate-stage hepatocellular carcinoma</article-title><source>Nat Rev Clin Oncol</source><year>2014</year><volume>11</volume><issue>9</issue><fpage>525</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2014.122</pub-id><pub-id pub-id-type="pmid">25091611</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>MC</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>XP</given-names></name><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>YJ</given-names></name><name><surname>Chau</surname><given-names>GY</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>CC</given-names></name><name><surname>Choi</surname><given-names>YR</given-names></name><name><surname>Poon</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Surgery for intermediate and advanced hepatocellular carcinoma: a consensus report from the 5th Asia-Pacific primary liver Cancer expert meeting (APPLE 2014)</article-title><source>Liver Cancer</source><year>2016</year><volume>5</volume><issue>4</issue><fpage>245</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1159/000449336</pub-id><pub-id pub-id-type="pmid">27781197</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>JY</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Nan</surname><given-names>KJ</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>XF</given-names></name></person-group><article-title>Surgical resection improves long-term survival of patients with hepatocellular carcinoma across different Barcelona clinic liver Cancer stages</article-title><source>Cancer Manag Res</source><year>2018</year><volume>10</volume><fpage>361</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.2147/CMAR.S152707</pub-id><pub-id pub-id-type="pmid">29503583</pub-id></element-citation></ref></ref-list></back></article>